Immediate Impact
1 by Nobel laureates 4 from Science/Nature 73 standout
Citing Papers
Natural killer cell therapies
2024 StandoutNature
A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells
2024 Standout
Works of Sadhna Shankar being referenced
A phase 1, open label, dose escalation study of MGD009, a humanized B7-H3 x CD3 DART protein, in combination with MGA012, an anti-PD-1 antibody, in patients with relapsed or refractory B7-H3-expressing tumors.
2018
A phase 1, open-label, dose escalation study of enoblituzumab (MGA271) in pediatric patients with B7-H3-expressing relapsed or refractory solid tumors.
2017
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Sadhna Shankar | 298 | 509 | 292 | 400 | 27 | 1.2k | |
| Andrea Carter | 121 | 555 | 763 | 156 | 40 | 1.5k | |
| W. Anthony Smithson | 99 | 635 | 145 | 154 | 19 | 1.3k | |
| Marten R. Nijziel | 150 | 272 | 419 | 161 | 53 | 1.4k | |
| Virginia Dalton | 73 | 564 | 211 | 1027 | 17 | 1.7k | |
| Theresa B. Haddy | 215 | 239 | 216 | 60 | 43 | 1.1k | |
| Lucius F. Sinks | 232 | 325 | 177 | 239 | 50 | 1.7k | |
| C. Thomas Kisker | 196 | 166 | 603 | 190 | 56 | 1.6k | |
| Vijaya M. Joshi | 75 | 352 | 87 | 713 | 47 | 1.0k | |
| Jos P.M. Bökkerink | 101 | 440 | 212 | 143 | 42 | 1.6k | |
| Edwin N. Forman | 222 | 282 | 342 | 59 | 49 | 1.3k |
All Works
Loading papers...